托特罗定联合宁泌泰治疗女性膀胱过度活动症的临床疗效观察

The Clinical Efficacy of Tolterodine Combining Ningmitai Treated for Female Overactive Bladder

目的观察托特罗定联合宁泌泰治疗女性膀胱过度活动症(OAB)的临床疗效,探讨提高女性OAB疗效的治疗方法。方法选择确诊为女性OAB患者92例,随机分为对照组和观察组,对照组采用托特罗定治疗,观察组采用托特罗定联合宁泌泰治疗。治疗6周后比较两组患者平均24 h排尿次数、平均24 h尿失禁次数、初始尿意容量、最大膀胱压容量及临床疗效。结果两组患者在24 h排尿次数、平均24 h尿失禁次数、初始尿意容量、最大膀胱压容量等方面比较,差异具有统计学意义(P<0.05),观察组临床疗效优于对照组。结论药物治疗女性OAB时选择托特罗定联合宁泌泰治疗,可显著提高临床疗效。

Objective To observe the clinical efficacy of tolterodine combining ningmitai treatment for female overactive bladder（OAB）,and try to find a way that can improve the the treatment efficacy.Methods 92 female patients with OAB were selected and randomly divided into two groups,tolterodine group and combined drug group.After 6 weeks of treatment,the two groups were compared in the average frequency of 24 h urination,the average frequency of 24 h urinary incontinence,the initial urine volume,and maximum capacity of the bladder pressure etc..Results The clinical efficacy of the combined drug group improved significantly（P0.05）compared to the tolterodine group in the above mentioned aspects.Conclusion Tolterodine combining ningmitai can improve the clinical efficacy significantly for female OAB,which should be adopted in the clinical practice.